Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT003-QbG10 in Persistent Allergic Asthma
NCT00890734Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Apr 2009
- Primary completion
- Apr 2010
- Modality
- Antisense DNA, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing CYT003-QbG10 with Placebo (2 arms). Primary endpoints: Markers for inflammation and asthma, Asthma Control Questionnaire at 12 weeks and 1 more. Started Apr 2009; status: completed.
02
Drugs
CYT003-QbG10
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00890734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00890734.